

INVENTOR SEARCH

=> d ibib abs 114 1-1

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:576753 HCAPLUS Full-text

DOCUMENT NUMBER: 131:219169

TITLE: Cosmetic or pharmaceutical formulations
containing isoquercetin with antiviral activityINVENTOR(S): Buchholz, Herwig; Kraus, Christine; Wagner,
Annette; Meduski, Jerzy

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944578	A1	19990910	WO 1999-EP1104	19990220
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19809304	A1	19990909	DE 1998-19809304	19980305
CA 2322450	A1	19990910	CA 1999-2322450	19990220
EP 1059911	A1	20001220	EP 1999-913176	19990220
EP 1059911	B1	20050420		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE, IE				
JP 2002505267	T	20020219	JP 2000-534181	19990220
AT 293433	T	20050515	AT 1999-913176	19990220
US 2002151599	A1	20021017	US 1999-349713	19990708
PRIORITY APPLN. INFO.:			DE 1998-19809304	A 19980305
			WO 1999-EP1104	W 19990220

AB Solid or liquid formulations contain isoquercetin as a natural flavonoid. The isoquercetin is contained as a light protection filter and/or an antiviral substance. The invention relates to both cosmetic and pharmaceutical formulations. Thus, a lipstick contained isoquercetin 0.1, Cremophor A-25 20.0, Cetirol HE 22.0, glycerin 5.0, preservative q.s., and water to 100% by weight

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM REGISTRY AND HCAPLUS

=> d que stat 15

L1 4 SEA FILE=REGISTRY ABB=ON (SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC OXIDE)/CN
 L3 288381 SEA FILE=HCAPLUS ABB=ON L1 OR SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC OXIDE
 L4 44662 SEA FILE=HCAPLUS ABB=ON L3 AND (?PIGMENT? OR ?INK? OR ?LACQUER? OR ?PLASTIC?)
 L5 17 SEA FILE=HCAPLUS ABB=ON L4 AND ?HERPES?

=> d ibib abs 15 1-17

L5 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:941793 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:308193
 TITLE: Anti-infective formulation comprising solvent vehicle and solidifying agent
 INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S. Ser. No. 146,917.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 17
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007196325	A1	20070823	US 2006-640101	20061214
US 2005276842	A1	20051215	US 2005-146917	20050606
PRIORITY APPLN. INFO.:			US 2004-577536P	P 20040607
			US 2005-146917	A2 20050606
			US 2005-750465P	P 20051214
			US 2005-750522P	P 20051214
			US 2005-750637P	P 20051214

AB The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. Thus, adhesive solidifying formulation was prepared containing ethanol 26%, Eudragit RL PO 44%, isostearic acid 26%, diisopropanol amine 2% and acyclovir 2%.

L5 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:670138 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:102133

10/553,668

TITLE: Compositions and methods for treating dermatological conditions
 INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay
 PATENT ASSIGNEE(S): Zars, Inc., USA
 SOURCE: PCT Int. Appl., 74pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 17
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070643	A2	20070621	WO 2006-US47747	20061214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
 US 2005-750465P P 20051214
 US 2005-750522P P 20051214
 US 2005-750524P P 20051214
 US 2005-750637P P 20051214

AB The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various dermatol. conditions, such as a bacterial infection, a virus infection, a fungal infection, alopecia, dermatitis, psoriasis, or photodamaged skin. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. Thus, an adhesive solidifying formulation was prepared containing acyclovir 3%, ethanol 21%, Eudragit RL-PO 15%, isostearic acid 31%, and trolamine 30%. The formulation provided significant penetration of the active ingredient through hairless mouse and human skin, which was greater than the marketed Zovirax cream. The combination of isostearic acid and trolamine enhanced the flux of acyclovir. The formulation showed a sustained delivery of acyclovir for up to 8 h. It is reasonable to assume based on the drug load and the continued presence of the non-volatile solvent that the delivery of acyclovir would continue at the reported flux values for as long as the subject desires to leave the adhesive solidifying formulation affixed to the skin.

L5 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1256641 HCAPLUS Full-text
 DOCUMENT NUMBER: 146:50262

10/553,668

TITLE: Antibiotic kit and compositions
 INVENTOR(S): Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir
 PATENT ASSIGNEE(S): Foamix Ltd., Israel
 SOURCE: U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 21
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006269485	A1	20061130	US 2006-448490	20060607
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005069566	A1	20050331	US 2004-911367	20040804
US 2006140984	A1	20060629	US 2005-532618	20051222
WO 2007099396	A2	20070907	WO 2006-IB3975	20060607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007292355	A1	20071220	US 2007-732547	20070404
PRIORITY APPLN. INFO.:				
			US 2002-429546P	P 20021129
			US 2003-492385P	P 20030804
			WO 2003-IB5527	W 20031024
			US 2004-911367	A2 20040804
			US 2005-688244P	P 20050607
			US 2005-532618	A2 20051222
			IL 2002-152486	A 20021025
			US 2003-497648P	P 20030825
			US 2003-530015P	P 20031216
			US 2004-835505	A2 20040428
			US 2004-922358	A2 20040820
			US 2005-41921	A2 20050124
			US 2006-789186P	P 20060404
			US 2006-448490	A2 20060607
			US 2006-861620P	P 20061129
			US 2007-880434P	P 20070112

AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition

L5 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1099617 HCAPLUS Full-text

DOCUMENT NUMBER: 145:432172

TITLE: Method for the treatment of herpes zoster with post-herpetic neuralgia in elderly patients with organic personality disorder

INVENTOR(S): Arsenenko, L. D.; Arsenenko, A. S.; Sereda, T. V.

PATENT ASSIGNEE(S): Gos. Obrazovatel'noe Uchrezhd. Dopolnitel'nogo Prof.

Obrazovan. Minister. Obrazovan. Ross. Fed.

Novokuznetskii Gos. Inst. Usovershenstvovaniya

Vrachei, Russia

SOURCE: Russ., 12pp.

CODEN: RUXXE7

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
RU 2285528	C2	20061020	RU 2004-138166	20041227
PRIORITY APPLN. INFO.:			RU 2004-138166	20041227

AB Method is disclosed for the treatment of herpes zoster with post-herpetic neuralgia in elderly patients with organic personality disorder. The invention relates to a method for the treatment of post-herpetic neuralgia in elderly patients with organic disorders of personality. Method involves combination therapy with antiviral agents, immunomodulators, analgesics, nootropic agents, metabolites, cerebroprotective agents, antidepressants and prepns. with hypocholesterolemic effect taken in the definite doses and regimen of their administration. Method provides the effective treatment based on the complex effect on different pathogenetic links of the disease and taking into account the specific aging and nervous-psychic features of patients of this group. Method ensures the enhanced effectiveness of treatment.

L5 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1094143 HCAPLUS Full-text

DOCUMENT NUMBER: 145:426012

TITLE: Foamable oil in water emulsion composition comprising polymer

INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Besonov, Alex; Eini, Meir

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 532,618.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 21
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006233721	A1	20061019	US 2006-389742	20060327
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005069566	A1	20050331	US 2004-911367	20040804
ZA 2005003298	A	20060830	ZA 2005-3298	20050425
US 2006140984	A1	20060629	US 2005-532618	20051222
AU 2006201878	A1	20070927	AU 2006-201878	20060504
WO 2007102052	A2	20070913	WO 2006-IB4170	20060914
WO 2007102052	A3	20080103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.:
 IL 2002-152486 A 20021025
 US 2002-429546P P 20021129
 US 2003-492385P P 20030804
 WO 2003-IB5527 W 20031024
 US 2004-911367 A2 20040804
 US 2005-717058P P 20050914
 US 2005-532618 A2 20051222
 US 2006-389742 A 20060327

AB The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. For example, emulsion composition was prepared comprising mineral oil 5.6%, iso-Pr myristate 5.6%, glyceryl monostearate 0.45%, PEG-40 stearate 2.6%, stearyl alc. 0.85%, Xanthan gum

0.26%, methocel K100M 0.26%, Polysorbate 80 0.90%, water 74.88%, preservative 0.60 and propellant 8%.

L5 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:759629 HCAPLUS Full-text
 DOCUMENT NUMBER: 145:195180
 TITLE: Cosmetic composition comprising hydrophobic and hydrophilic silica particles
 INVENTOR(S): Ingman, Dov
 PATENT ASSIGNEE(S): Or-Le-Or Ltd., Israel
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1685824	A1	20060802	EP 2006-100458	20060117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CA 2534306	A1	20060730	CA 2006-2534306	20060130
US 2006257437	A1	20061116	US 2006-341872	20060130
PRIORITY APPLN. INFO.:			IL 2005-166646	A 20050130

AB The present invention relates to a new topical cosmetic composition formulated for concealing wrinkles and for eliminating or reducing damages to the skin appearance resulted from a wide variety of disorders, such as for example, acne. The composition comprises water, optionally containing 25 to 400 ppm of Ag, hydrophobic particles, preferably hydrophobic silica, having a diameter, ranged from about 5 to about 150 nm, and/or hydrophilic particles, preferably hydrophilic silica, having a diameter, ranged from about 5 to about 150 nm and a soluble electrolyte, capable of releasing free ions in an aqueous environment. Thus, a hypotonic composition for treating acne comprised Dead Sea salt 0.2, zinc sulfate 1, hydrophobic silica 5, hydrophilic silica 5, tea tree oil 2, sea buckthorn oil 3, vitamin A 0.1, vitamin C 1.5, vitamin E acetate 0.1, methylparaben 0.1, propylene glycol 2, and water 80%, resp. A composition comprising water, optionally containing Ag 25 to 400 ppm, 10 weight% Aerosil 380, 2.5 weight% Aerosil R812, 1 to 20 weight% Dead Sea salt, and optionally one or more conventional skincare and/or anti-acne agent, selected from evening primrose oil, sweet almond oil, sea buckthorn oil, tea tree oil, Finsolv TN, (C12-15 alkyl benzoate), octyl hydroxystearate, salicylic acid, vitamin C, citric acid, azelaic acid, benzoyl peroxide, zinc acetate and sulfur. The composition was highly effective in treating acne. The concentration of the salt in such composition was determined according to the treated skin type (dried, oily, etc.) and the particular acne type, grade and state of the treated individual. Compns. containing higher concns. of salt (10 to 20 weight%) are preferred for treating an oily skin and an intensive acne state.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1291998 HCAPLUS Full-text
 DOCUMENT NUMBER: 144:40803
 TITLE: Vasoactive kit and compositions comprising emollients and polymeric additive
 INVENTOR(S): Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini,

Meir
 PATENT ASSIGNEE(S): Foamix Ltd., Israel
 SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S.
 Ser. No. 911,367.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 21
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005271596	A1	20051208	US 2005-124676	20050509
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005069566	A1	20050331	US 2004-911367	20040804
ZA 2005003298	A	20060830	ZA 2005-3298	20050425
AU 2006201878	A1	20070927	AU 2006-201878	20060504
AU 2006283225	A1	20070301	AU 2006-283225	20060508
WO 2007023396	A2	20070301	WO 2006-IB3525	20060508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007020213	A1	20070125	US 2006-488989	20060719
US 2007292359	A1	20071220	US 2007-811140	20070607
PRIORITY APPLN. INFO.:				
			IL 2002-152486	A 20021025
			US 2002-429546P	P 20021129
			US 2003-492385P	P 20030804
			WO 2003-IB5527	W 20031024
			US 2004-911367	A2 20040804
			US 2003-497648P	P 20030825
			US 2003-530015P	P 20031216
			US 2004-835505	A2 20040428
			US 2004-922358	A2 20040820
			US 2005-78902	A2 20050311
			US 2005-124676	A 20050509
			US 2005-696878P	P 20050706
			US 2005-700702P	P 20050719
			US 2005-532618	A2 20051222
			US 2006-781868P	P 20060313
			WO 2006-IB3525	W 20060508

US 2006-811627P	P	20060607
US 2006-481596	A2	20060706
US 2006-488989	A2	20060719
US 2007-897638P	P	20070126
US 2007-899176P	P	20070202
US 2007-717897	A2	20070313

AB The present invention relates to a therapeutic kit to provide an effective dosage of a vasoactive agent, including an aerosol packaging assembly with a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam. The pressurized product comprises a foamable composition including: a vasoactive agent; a carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. thereof at 2-50% by weight, a surfactant, 0.01-5% by weight of at least 1 polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of 3-25% by weight of the total composition

L5 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:904090 HCAPLUS Full-text

DOCUMENT NUMBER: 143:235474

TITLE: Cosmetic and pharmaceutical foam with solid particles such as oxides for topical administration

INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir; Besonov, Alex

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 18 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005186147	A1	20050825	US 2005-50999	20050204
AU 2005201455	A1	20050825	AU 2005-201455	20050204
PRIORITY APPLN. INFO.:			US 2004-541698P	P 20040204

AB The invention relates to an alc.-free cosmetic or pharmaceutical foam carrier comprising about 2 to 30% by weight solid particles, about 2 to 75% by weight hydrophobic solvent, about 10 to 85% by weight water, about 0.1 to 5% by weight surface-active agent, about 0.1 to 5% by weight stabilizer/gelling agent and a liquefied or compressed gas propellant in a container, which upon release provides a breakable foam suitable for topical administration. For example, a wound healing foam was prepared containing mineral oil 12.5, colloidal silver 2.0, lidocaine 4.0, Arlacel 135 2.0, Avicel CL611 2.0, Tween 80 2.0, cocoamidopropylbetaine 1.0, D-Panthenol 50P 10.0, benzalkonium chloride 0.20 and water to 100%.

L5 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:904087 HCAPLUS Full-text

DOCUMENT NUMBER: 143:235471

TITLE: Kit and composition of imidazole with enhanced bioavailability and therapeutic uses thereof

INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 911,367.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 21

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005186142	A1	20050825	US 2005-41921	20050124
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005069566	A1	20050331	US 2004-911367	20040804
ZA 2005003298	A	20060830	ZA 2005-3298	20050425
AU 2005204347	A1	20060810	AU 2005-204347	20050830
CA 2602042	A1	20070628	CA 2006-2602042	20060124
WO 2007072216	A2	20070628	WO 2006-IB3974	20060124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006201878	A1	20070927	AU 2006-201878	20060504
US 2007292355	A1	20071220	US 2007-732547	20070404
IN 2007CN03681	A	20071116	IN 2007-CN3681	20070823
PRIORITY APPLN. INFO.:			IL 2002-152486	A 20021025
			US 2003-492385P	P 20030804
			WO 2003-IB5527	A 20031024
			US 2004-911367	A2 20040804
			US 2002-429546P	P 20021129
			US 2003-497648P	P 20030825
			US 2003-530015P	P 20031216
			US 2004-835505	A2 20040428
			US 2004-922358	A2 20040820
			US 2005-41921	A 20050124
			US 2005-688244P	P 20050607
			US 2005-532618	A2 20051222
			WO 2006-IB3974	W 20060124
			US 2006-789186P	P 20060404
			US 2006-448490	A2 20060607
			US 2006-861620P	P 20061129
			US 2007-880434P	P 20070112

AB The present inventino relates to a composition and therapeutic kit comprising therapeutic azole with increased solubility The kit includes an aerosol

packaging assembly containing a container accommodating a pressurized product and an outlet capable of releasing the pressurized product as a foam. The pressurized product includes a foamable composition including: i. a therapeutic azole, wherein the solubility of the azole in the composition before foaming is less than the solubility of the azole in the composition after foaming; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a co-solvent, an emollient and mixts. thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition

L5 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:902663 HCAPLUS Full-text

DOCUMENT NUMBER: 143:235459

TITLE: Cosmetic and pharmaceutical foam with solid particles such as oxides for topical administration

INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir; Besonov, Alex

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076697	A2	20050825	WO 2005-IB1227	20050204
WO 2005076697	A3	20070419		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA			
AU 2005201455	A1	20050825	AU 2005-201455	20050204
CA 2555121	A1	20050825	CA 2005-2555121	20050204
EP 1727522	A2	20061206	EP 2005-726422	20050204
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
IN 2006KN02512	A	20070601	IN 2006-KN2512	20060901
PRIORITY APPLN. INFO.:			US 2004-541698P	P 20040204
			WO 2005-IB1227	W 20050204

AB The invention relates to an alc.-free cosmetic or pharmaceutical foam carrier comprising about 2 to 30% by weight solid particles, about 2 to 75% by weight hydrophobic solvent, about 10 to 85% by weight water, about 0.1 to 5% by weight surface-active agent, about 0.1 to 5% by weight stabilizer/gelling agent and a liquefied or compressed gas propellant in a container, which upon release provides a breakable foam suitable for topical administration. For

example, a wound healing foam was prepared containing mineral oil 12.5, colloidal silver 2.0, lidocaine 4.0, Arlacel 135 2.0, Avicel CL611 2.0, Tween 80 2.0, cocoamidopropylbetaine 1.0, D-Panthenol 50P 10.0, benzalkonium chloride 0.20 and water to 100%.

L5 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:878561 HCAPLUS Full-text

DOCUMENT NUMBER: 141:346084

TITLE: Device for analysis or separation containing an active nanostructured carrier, its preparation method and applications

INVENTOR(S): Zou, Fanglin; Chen, Chunsheng; Chen, Ning; Wang, Jianxia

PATENT ASSIGNEE(S): Chengdu Kuachang Medical Industrial Limited, Peop. Rep. China; Chengdu Kuachang Science & Technology Co., Ltd

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004090548	A1	20041021	WO 2004-CN203	20040315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CN 1434295	A	20030806	CN 2003-117446	20030313
CN 1514243	A	20040721	CN 2003-117787	20030430
WO 2004081571	A1	20040923	WO 2004-CN77	20040120
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004102196	A1	20041125	WO 2004-CN437	20040430
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

10/553,668

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

CN 1697975	A	20051116	CN 2004-80000653	20040430
EP 1624306	A1	20060208	EP 2004-730459	20040430
R: DE, FR, GB, IT				
JP 2007502998	T	20070215	JP 2006-529552	20040430
US 2006057631	A1	20060316	US 2005-258996	20051027
PRIORITY APPLN. INFO.:			CN 2003-117446	A 20030313
			CN 2003-117787	A 20030430
			WO 2004-CN77	A 20040120
			WO 2004-CN203	A 20040315
			WO 2004-CN437	W 20040430

AB The invention relates to an active nanostructured carrier with high sensitivity for separation and/or anal., its preparation method, and a nano-label and its labeling method. The invention also relates to a biochip and a polypeptide detection device, all of which contain the high-sensitive active nanostructured carrier and /or the nano-label, especially anal. chips, enzyme labeling plates and chromatog. test strips, and their applications.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:352956 HCAPLUS Full-text

DOCUMENT NUMBER: 140:363037

TITLE: Formulations for topical delivery of bioactive substances and methods for their use

INVENTOR(S): Vromen, Jacob

PATENT ASSIGNEE(S): Australian Importers Ltd., USA

SOURCE: U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004081681	A1	20040429	US 2002-281062	20021025
US 7241456	B2	20070710		
CA 2543370	A1	20040513	CA 2003-2543370	20031015
WO 2004039348	A1	20040513	WO 2003-US32638	20031015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282834	A1	20040525	AU 2003-282834	20031015
EP 1558206	A1	20050803	EP 2003-774832	20031015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2007071711	A1	20070329	US 2006-535213	20060926
PRIORITY APPLN. INFO.:			US 2002-281062	A 20021025
			WO 2003-US32638	W 20031015

AB The invention relates to topical delivery of bioactive agents. More particularly, the invention relates to anhydrous formulations for percutaneous absorption. The invention provides formulations that allow efficient topical delivery of high concns. of bioactive substances for percutaneous absorption. The formulations according to the invention are generally non-irritating to the skin. A preferred topical formulation comprises (1) anhydrous media containing glycerin, propylene glycol, capric/caprylic triglyceride, cetearyl alc., d-tocopherol, ascorbyl palmitate, thioldipropionic acid, BHT, phenoxyethanol, and parabens and (2) bioactive substances containing micronized niacinamide, micronized acetylsalicylic acid, and micronized ascorbic acid.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:595341 HCAPLUS Full-text

DOCUMENT NUMBER: 137:159019

TITLE: Products for topical applications comprising oil bodies

INVENTOR(S): Deckers, Harm M.; Van Rooijen, Gijs; Boothe, Joseph; Goll, Janis; Moloney, Maurice M.

PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Can.

SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 577,147.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2002106337	A1	20020808	US 2001-983546	20011024
US 6599513	B2	20030729		
IN 190035	A1	20030531	IN 1998-DE1401	19980525
ZA 9804459	A	19990413	ZA 1998-4459	19980526
US 6146645	A	20001114	US 1998-84777	19980527
US 6183762	B1	20010206	US 1999-448600	19991124
CA 2290278	A1	20010524	CA 1999-2290278	19991124
CA 2290278	C	20030729		
US 6372234	B1	20020416	US 2000-577147	20000524
AU 772919	B2	20040513	AU 2001-85511	20011029
IN 195229	A1	20050128	IN 2002-DE1185	20021125
PRIORITY APPLN. INFO.:			US 1997-47753P	P 19970527
			US 1997-47779P	P 19970527
			US 1998-75863P	P 19980225
			US 1998-75864P	P 19980225
			US 1998-84777	A2 19980527
			US 1999-448600	A2 19991124
			US 2000-577147	A2 20000524
			IN 1998-DE1401	A3 19980525
			AU 1998-75178	A3 19980527

AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatol. products. A stabilized oil body formulation contained Safflower oils 96.50, Keltrol CG 0.70, Arlacel-165 2.50, phytic acid 0.10, and Glydant Plus 0.20%. A low detergent active body wash formulation comprised cetyl hydroxyethyl cellulose 1.00, Miracare BT 5.00,

lauramide DEA 3.00, glycerin 3.00, Na2EDTA 0.05, Polysorbate-20 0.5, Glydant Plus 0.1, lanolin alc. 1.00, petrolatum 3.00, 30% ammonium lauryl sulfate 15.0, the above stabilized oil bodies 25.0, and citric acid 0.89%, water and fragrance qs.

L5 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:555377 HCAPLUS Full-text

DOCUMENT NUMBER: 137:99039

TITLE: Stabilized brivudine topical formulations containing oxide pigments

INVENTOR(S): Gehlert, Ulrike; Groeger, Karsten; Schmitz, Reinhard; Schrader, Karl-Heinz; Schrader, Andreas; Wihsmann, Marc; Maggi, Carlo Alberto; Manzini, Stefano; Stubinski, Bettina

PATENT ASSIGNEE(S): Berlin-Chemie A.-G., Germany; Menarini Ricerche S.p.A.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056913	A2	20020725	WO 2002-EP163	20020110
WO 2002056913	A3	20021107		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2434743	A1	20020725	CA 2002-2434743	20020110
AU 2002244642	A1	20020730	AU 2002-244642	20020110
EE 200300322	A	20031015	EE 2003-322	20020110
HU 2003002741	A2	20031128	HU 2003-2741	20020110
HU 2003002741	A3	20070628		
EP 1365772	A2	20031203	EP 2002-712810	20020110
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002006478	A	20031230	BR 2002-6478	20020110
JP 2004519460	T	20040702	JP 2002-557420	20020110
RU 2280453	C2	20060727	RU 2003-121639	20020110
IN 2003DN01070	A	20070105	IN 2003-DN1070	20030708
BG 107988	A	20040930	BG 2003-107988	20030710
MX 2003PA06307	A	20030916	MX 2003-PA6307	20030714
NO 2003003206	A	20030715	NO 2003-3206	20030715
ZA 2003005437	A	20040715	ZA 2003-5437	20030715
US 2004087602	A1	20040506	US 2003-466305	20031219
PRIORITY APPLN. INFO.:			EP 2001-100968	A 20010117
			WO 2002-EP163	W 20020110

AB The use of metal oxide pigments as photodegrdn. stabilizers in topical compns. containing brivudine. is disclosed. Thus, a hydrogel contained brivudine 5, TiO2 21.25, Al2O3 1.25, silica 0.125, glycerol 2.375, iron oxide yellow 3.25, iron oxide red 1.25, iron oxide black 0.5, propylene glycol 20, Paraffinum

subliquidum 5, iso-Pr myristate 5, cetyl alc. 3, polyoxyethylene monostearate 0.8, hydroxyethyl cellulose 0.3, citric acid qs and water to 100 g.

L5 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:293380 HCAPLUS Full-text

DOCUMENT NUMBER: 128:312936

TITLE: Antiherpetic topical pharmaceutical compositions containing acyclovir

INVENTOR(S): Santus, Giancarlo; Golzi, Roberto; Garavaglia, Antonio

PATENT ASSIGNEE(S): Recordati S.A. Chemical and Pharmaceutical Company, Italy

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818472	A1	19980507	WO 1997-EP6022	19971031
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2270254	A1	19980507	CA 1997-2270254	19971031
AU 9869078	A	19980522	AU 1998-69078	19971031
AU 724741	B2	20000928		
EP 948332	A1	19991013	EP 1997-948849	19971031
EP 948332	B1	20030903		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
CN 1235547	A	19991117	CN 1997-199317	19971031
BR 9712610	A	19991221	BR 1997-12610	19971031
NZ 335685	A	20000327	NZ 1997-335685	19971031
JP 2001503404	T	20010313	JP 1998-520070	19971031
AT 248597	T	20030915	AT 1997-948849	19971031
KR 2000052678	A	20000825	KR 1999-703461	19990420
NO 9901910	A	19990621	NO 1999-1910	19990421
MX 9903904	A	20000228	MX 1999-3904	19990427
PRIORITY APPLN. INFO.:			IT 1996-MI2258	A 19961031
			WO 1997-EP6022	W 19971031

AB Described are antiherpetic pharmaceutical compns. suitable for administration by means of a topical applicator (a stick or a medicated roll-on stick). These compns. contain acyclovir (I) or any of its derivs., either alone or associated with vitamin A or any of its esters, as an active ingredient, and are useful in particular for the treatment of herpes labialis. Thus, 5% micronized I was dispersed under stirring at 60° up to homogeneous dispersion in a fatty phase made up of carnauba wax 10, beeswax 15, lanolin 5, cetyl alc. 5, hydrogenated castor oil 60%, the melted mass containing I was then filled into 3 gal cylindrical containers for sticks. The efficacy and comfort of use of the composition in 30 patients with herpes labialis is reported.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:195630 HCAPLUS Full-text

DOCUMENT NUMBER: 126:190940

TITLE: Topical pharmaceutical compositions containing
volatile oils, silicones, and active ingredients
INVENTOR(S): Grollier, Jean-Francois; Allec, Josiane; Agostini,
Isabelle

PATENT ASSIGNEE(S): L'Oreal S. A., Fr.

SOURCE: Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 755675	A1	19970129	EP 1996-401491	19960705
EP 755675	B1	19970917		
R: DE, ES, FR, GB, IT				
FR 2737118	A1	19970131	FR 1995-9252	19950728
FR 2737118	B1	19970905		
ES 2109832	T3	19980116	ES 1996-401491	19960705
AU 9659430	A	19970213	AU 1996-59430	19960710
AU 679663	B2	19970703		
CA 2182226	A1	19970129	CA 1996-2182226	19960726
JP 09040548	A	19970210	JP 1996-198146	19960726
JP 2965510	B2	19991018		
US 6136332	A	20001024	US 1996-688027	19960729
PRIORITY APPLN. INFO.:			FR 1995-9252	A 19950728

OTHER SOURCE(S): MARPAT 126:190940

AB The title pharmaceutical containing volatile oils, Ph silicones, and active ingredients are claimed. A pliable paste contained cyclopentadimethylsiloxane 45, polyphenylmethylsiloxane 25, silicone wax 10, polyethylene wax 5, alkyl dimethicone 5, titanium dioxide 5, Nylon 3, and fusidic acid 2g.

L5 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:239633 HCAPLUS Full-text

DOCUMENT NUMBER: 120:239633

TITLE: Devices and methods for detection of an analyte based
upon light interference

INVENTOR(S): Bogart, Gregory R.; Moddel, Garret R.; Maul, Diana M.;
Etter, Jeffrey B.; Crosby, Mark; Miller, John B.;
Blessing, James; Kelley, Howard; Sandstrom, Torbjorn;
Stibler, Lars

PATENT ASSIGNEE(S): Biostar, Inc., USA

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9403774	A1	19940217	WO 1993-US5673	19930610
W: AT, AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9179004	A	19921021	AU 1991-79004	19910320

AU 653940	B2	19941020		
EP 539383	A1	19930505	EP 1991-910056	19910320
EP 539383	B1	19960918		
R: BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05506936	T	19931007	JP 1991-509344	19910320
JP 3193373	B2	20010730		
ES 2094224	T3	19970116	ES 1991-910056	19910320
JP 2001235473	A	20010831	JP 2000-287242	19910320
AU 9345360	A	19940303	AU 1993-45360	19930610
JP 07509565	T	19951019	JP 1994-505280	19930610
JP 3506703	B2	20040315		
EP 727038	A1	19960821	EP 1993-915341	19930610
EP 727038	B1	20051214		
R: ES, FR, GB, IT, SE				
EP 1126278	A2	20010822	EP 2001-108521	19930610
EP 1126278	A3	20011017		
EP 1126278	B1	20070523		
R: ES, FR, GB, IT, SE				
JP 2002116208	A	20020419	JP 2001-236186	19930610
JP 3507048	B2	20040315		
JP 2002139498	A	20020517	JP 2001-236144	19930610
JP 3456984	B2	20031014		
EP 1635162	A2	20060315	EP 2005-27236	19930610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
HK 1003304	A1	20041013	HK 1998-102353	19980319
JP 2002122601	A	20020426	JP 2001-236166	20010803
JP 3673849	B2	20050720		
JP 2002122603	A	20020426	JP 2001-236198	20010803
JP 3547723	B2	20040728		
JP 2005049356	A	20050224	JP 2004-276389	20040924
JP 3787143	B2	20060621		

PRIORITY APPLN. INFO.:

US 1992-924343	A	19920731
EP 1991-910056	A	19910320
JP 1991-509344	A3	19910320
WO 1991-US1781	A	19910320
EP 1993-915341	A3	19930610
JP 1994-505280	A3	19930610
WO 1993-US5673	W	19930610
JP 2001-236166	A3	20010803

AB Methods for analyzing an optical surface for an analyte of interest in a test sample and related instruments/devices are disclosed. The method entails the use of a thin-film optical immunoassay device whereby an analyte of interest is detected in a test sample through spectral changes in the light impinging on the surface prior to and after the binding of the analyte to a reactive substrate layer(s). The device includes a substrate which has a 1st color in response to light impinging thereon. The substrate also exhibits a 2nd color which is different from the 1st color. The 2nd color is exhibited in response to the same light when the analyte is present on the surface. Thus, SiO was vapor deposited on a polished monocryst. Si wafer to a thickness of 550 Å; the film had a golden interference color. The film was activated with N-(2-aminoethyl)-3-aminopropyltrimethoxysilane, coated with a DNP-albumin conjugate to a thickness of 40Å, rinsed, and dried. The coated wafer was used in a competitive immunoassay for DNP using goat anti-DNP antibody and an ellipsometer to measure the change in mass at the surface from the change in light intensity.

RESULTS FROM MEDLINE, BIOSIS, KOSMET, RAPRA, EMBASE, AND DRUGU

=> => d que stat l18

L1 4 SEA FILE=REGISTRY ABB=ON (SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC OXIDE)/CN
 L16 24737 SEA L1 OR SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC OXIDE
 L17 5274 SEA L16 AND (?PIGMENT? OR INK? OR ?LACQUER? OR ?PLASTIC?)
 L18 6 SEA L17 AND ?HERPES?

=> d ibib abs l18 1-6

L18 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:202468 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200600204867
 TITLE: LMP1 signaling and activation of NF-kappa B in LMP1 transgenic mice.
 AUTHOR(S): Thornburg, N. J.; Kulwichit, W.; Edwards, R. H.; Shair, K. H. Y.; Bendt, K. M.; Raab-Traub, N. [Reprint Author]
 CORPORATE SOURCE: Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Immunol Microbiol, CB 7295, Room 102, Mason Farm Rd, Chapel Hill, NC 27599 USA
 nrt@med.unc.edu
 SOURCE: Oncogene, (JAN 2006) Vol. 25, No. 2, pp. 288-297.
 CODEN: ONCNES. ISSN: 0950-9232.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 22 Mar 2006
 Last Updated on STN: 22 Mar 2006

AB Transgenic mice expressing Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) under the control of an immunoglobulin heavy-chain promoter and enhancer develop lymphoma at a threefold higher incidence than LMP1-negative mice. In vitro, LMP1 activates numerous signaling pathways including p38, c-Jun N terminal kinase (JNK), phosphatidylinositol 3 kinase (PI3K)/Akt, and NF-kappa B through interactions with tumor necrosis receptor-associated factors (TRAFs). These pathways are frequently activated in EBV-associated malignancies, although their activation cannot be definitively linked to LMP1 expression in vivo. In this study, interactions between LMP1 and TRAFs and the activation of PI3K/Akt, JNK, p38, and NF-kappa B were examined in LMP1 transgenic mice. LMP1 co-immunoprecipitated with TRAFs 1, 2, and 3. Akt, JNK, and p38 were activated in LMP1-positive and -negative splenocytes as well as LMP1-positive and -negative lymphomas. Multiple forms of NF-kappa B were activated in healthy splenocytes from LMP1 transgenic mice, in contrast to healthy splenocytes from LMP1-negative mice. However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-kappa B c-Rel, was specifically activated. Similarly to EBV-associated malignancies, p53 protein was detected at high levels in the transgenic lymphomas, although mutations were not detected in the p53 gene. These data indicate that NF-kappa B is activated in LMP1-positive healthy splenocytes; however, NF-kappa B c-Rel is specifically activated in both the transgenic lymphomas and in the rare lymphomas that develop in negative mice. The LMP1-mediated activation of NF-kappa B may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.

L18 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 ACCESSION NUMBER: 2000:124940 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200000124940
 TITLE: A dermatology ward at the beginning of the 20th century.

AUTHOR(S): Albert, Michael R. [Reprint author]; Mackool, Bonnie T.
CORPORATE SOURCE: Dermatology Branch, National Cancer Institute, NIH, 10
Center Dr, Building 10, 12N262, Bethesda, MD, 20892-1908,
USA
SOURCE: Journal of the American Academy of Dermatology, (Jan.,
2000) Vol. 42, No. 1 Part 1, pp. 113-123. print.
ISSN: 0190-9622.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 5 Apr 2000
Last Updated on STN: 3 Jan 2002

L18 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER: 1997:54500 BIOSIS Full-text
DOCUMENT NUMBER: PREV199799353703
TITLE: Increased expression of NF-kappa-B proteins P65, P50 and
c-Rel in immunodeficiency-related EBV positive non
Hodgkin's lymphomas.
AUTHOR(S): Feuillard, J.; Martin, A.; Asso-Bonnet, M.; Davi, F.; El
Mansouri, S.; Raphael, M.
CORPORATE SOURCE: Hematol. Surgical Pathol., Avicenne Hospital, UFR, SMBH
Bobigny, URA CNRS 625, Pitie Salpetriere, Paris, France
SOURCE: Blood, (1996) Vol. 88, No. 10 SUPPL. 1 PART 1-2, pp. 380A.
Meeting Info.: Thirty-eighth Annual Meeting of the American
Society of Hematology. Orlando, Florida, USA. December
6-10, 1996.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Feb 1997
Last Updated on STN: 5 Feb 1997

L18 ANSWER 4 OF 6 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights
reserved on STN
ACCESSION NUMBER: 2006576090 EMBASE Full-text
TITLE: Incorporating Photodynamic Therapy into a Medical and
Cosmetic Dermatology Practice.
AUTHOR: Gilbert D.J.
CORPORATE SOURCE: Dr. D.J. Gilbert, Newport Dermatology and Laser Associates,
1441 Avacado, Newport Beach, CA 92660, United States.
lazrdoc@pacbell.net
SOURCE: Dermatologic Clinics, (Jan 2007) Vol. 25, No. 1, pp.
111-118.
Refs: 17
ISSN: 0733-8635 CODEN: DRMCDJ
PUBLISHER IDENT.: S 0733-8635(06)00100-8
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 013 Dermatology and Venereology
030 Clinical and Experimental Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Dec 2006
Last Updated on STN: 12 Dec 2006

AB ALA-PDT is a safe, effective, and easy-to-perform procedure for the treatment of a variety of cutaneous conditions. Pretreatment and posttreatment procedures are straightforward and well documented. Adverse effects are mild, temporary, and easily managed. Light sources may already be available in physicians' offices or may be purchased for \$8000. Cosmetic benefits of ALA-PDT encourage patients to seek additional cosmetic treatments, increasing practice revenue. .COPYRGT. 2006 Elsevier Inc. All rights reserved.

L18 ANSWER 5 OF 6 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1996129090 EMBASE Full-text
 TITLE: [Sun-induced skin damage].
 SCHADWIRKUNGEN DER SONNENSTRAHLUNG AN DER HAUT.
 AUTHOR: Raab W.
 CORPORATE SOURCE: Prof. Dr. W. Raab, Walfischgasse 3, A-1010 Wien 1, Austria
 SOURCE: Aktuelle Dermatologie, (1996) Vol. 22, No. SUPPL. 1, pp. 2-6.
 ISSN: 0340-2541 CODEN: AKDEDY
 COUNTRY: Germany
 DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
 FILE SEGMENT: 013 Dermatology and Venereology
 037 Drug Literature Index
 LANGUAGE: German
 SUMMARY LANGUAGE: English; German
 ENTRY DATE: Entered STN: 11 Jun 1996
 Last Updated on STN: 11 Jun 1996

AB Ultraviolet-induced skin lesions may be provoked via different mechanisms. Most frequently, an overload of the natural sun defense is encountered, resulting in sunburn - seen immediately - or in chronic sun damage emerging only after decades. With the increasing life expectancy, the symptoms of such a chronic sun damage are more and more often noticed by the dermatologist (skin dryness, premature skin ageing, pigmented spots, actinic keratoses, non-melanoma skin cancer). Other sun-induced skin lesions include specific dermatoses caused by ultraviolet rays ('sun-Kobner'), the consequences of immunosuppression (Herpes simplex 'solaris', LE, melanoma) and photodynamic reactions due to, for example, various drugs. True photodermatoses are only rarely seen, possibly due to the fact that their diagnosis is rather complicated and mild cases are misdiagnosed. - Sun protection in general and even more in the ever - increasing cases of pathological sun reactions is one of the most important tasks of the dermatologist. Problems of pigmentation, physical and chemical sun protection, strength of the sun protection 'factor' (effective only up to 60% of the erythema threshold dose!) must be discussed with the patient exhibiting sun-induced skin lesions or just asking for advice.

L18 ANSWER 6 OF 6 DRUGU COPYRIGHT 2008 THE THOMSON CORP on STN

ACCESSION NUMBER: 1985-30177 DRUGU T M S Full-text
 TITLE: Titanium Pigmentation: An Electron Probe
 Microanalysis Study.
 AUTHOR: Dupre A; Tournon P; Daste J; Lassere J; Bonafe J L; Viraben R
 LOCATION: Toulouse, France
 SOURCE: Arch.Dermatol. (121, No. 5, 656-58, 1985) 6 Fig. 8 Ref.
 CODEN: ARDEAC ISSN: 0003-987X
 AVAIL. OF DOC.: Department de Dermatologie, Hopital de La Grave, Place Lange,
 31052 Toulouse Cedex, France.
 LANGUAGE: English
 DOCUMENT TYPE: Journal
 FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AN 1985-30177 DRUGU T M S Full-text

AB Following the use of a titanium dioxide-containing cream (Parkipan); other ingredients amyleine hydrate, trypan blue, white petrolatum, lanolin), for the treatment of herpetic erosive balanoposthitis, a patient developed a penile metallic pigmentation. Electron probe microanalysis showed that the pigmentation was probably due to deposition of titanium in the dermis facilitated by the presence of herpetic lesions.

ABEX A 22-yr-old man presented with asymptomatic, persistent, pearly, yellow pin-head sized shiny papules on the glans, sulcus and prepuce which had been present for 6 mth. The papules developed within 3 wk of starting treatment of herpetic lesions with Parkipan. Light microscopy showed normal skin morphology, except for the presence of brown granules in the upper part of the dermis. The granules were not in the epidermis or glandular structures. Polarized light microscopy failed to visualize the granules but dark field microscopy revealed refractive granules throughout the dermis. Under EM, the granules (500-600 nm diameter) were free in the dermis or located in macropahges, either free or within lysosome-like bodies. Electron probe microanalysis using energy dispersive analysis of X-ray (EDAX) films showed a major titanium peak for the pigment particles but not for surrounding tissues.

SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 16:51:05 ON 22 JAN 2008)

FILE 'REGISTRY' ENTERED AT 16:59:46 ON 22 JAN 2008

L1 4 SEA ABB=ON (SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC OXIDE)/CN
 L2 1 SEA ABB=ON (PIGMENTS OR INKS OR LACQUERS OR PLASTICS)/CN

FILE 'HCAPLUS' ENTERED AT 17:01:25 ON 22 JAN 2008

L3 288381 SEA ABB=ON L1 OR SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC
 OXIDE
 L4 44662 SEA ABB=ON L3 AND (?PIGMENT? OR ?INK? OR ?LACQUER? OR
 ?PLASTIC?)
 L5 17 SEA ABB=ON L4 AND ?HERPES?
 E BUCHHOLZ HERWIG/AU
 L6 102 SEA ABB=ON ("BUCHHOLZ HERWIG"/AU OR "BUCHHOLZ HERWIG A"/AU OR
 "BUCHHOLZ HERWING"/AU)
 E BICARD BENHAMOU VALERIE/AU
 L7 5 SEA ABB=ON "BICARD BENHAMOU VALERIE"/AU
 E BRUNNER MARKUS/AU
 L8 23 SEA ABB=ON ("BRUNNER MARKUS"/AU OR "BRUNNER MARKUS DIPL
 ING"/AU)
 E MEDUSKI JERZY/AU
 L9 33 SEA ABB=ON ("MEDUSKI J"/AU OR "MEDUSKI J W"/AU OR "MEDUSKI
 JERZY"/AU OR "MEDUSKI JERZY D"/AU OR "MEDUSKI JERZY W"/AU)
 L10 0 SEA ABB=ON L6 AND L7 AND L8 AND L9
 L11 147 SEA ABB=ON L6 OR L7 OR L8 OR L9
 L12 1 SEA ABB=ON L11 AND ?HERPES?
 L13 47 SEA ABB=ON L11 AND ?COSMETIC?
 L14 1 SEA ABB=ON L13 AND ?HERPES?
 L15 ANALYZE L14 1 CT : 11 TERMS

FILE 'MEDLINE, BIOSIS, RAPRA, KOSMET, EMBASE, DRUGU' ENTERED AT 17:08:22
ON 22 JAN 2008

L16 24737 SEA ABB=ON L1 OR SILVER OXIDE OR TITANIUM DIOXIDE OR ZINC
 OXIDE
 L17 5274 SEA ABB=ON L16 AND (?PIGMENT? OR INK? OR ?LACQUER? OR
 ?PLASTIC?)
 L18 6 SEA ABB=ON L17 AND ?HERPES?

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3
 DICTIONARY FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and

predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 21 Jan 2008 (20080121/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MEDLINE

FILE LAST UPDATED: 19 Jan 2008 (20080119/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 16 January 2008 (20080116/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE RAPRA

FILE LAST UPDATED: 9 JAN 2008 <20080109/UP>
FILE COVERS 1972 TO DATE

>>> Simultaneous left and right truncation is available in the basic index (/BI), and in the controlled term (/CT), geographical term (/GT), and non-polymer term (/NPT) fields. <<<

>>> The RAPRA Classification Code is available as a PDF file
>>> and may be downloaded free-of-charge from:
>>> http://www.stn-international.de/stdatabases/details/rapra_classcodes.

FILE KOSMET

FILE LAST UPDATED: 2 JAN 2008 <20080102/UP>

10/553,668

FILE COVERS 1968 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE EMBASE

FILE COVERS 1974 TO 21 Jan 2008 (20080121/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default)
and biweekly.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE
codes as part of the EMTREE thesaurus in EMBASE. Please update
your current-awareness alerts (SDIs) if they contain EMTREE
codes.

For further assistance, please contact your local helpdesk.

FILE DRUGU

FILE LAST UPDATED: 18 JAN 2008 <20080118/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<